Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis
- PMID: 20207007
- DOI: 10.1016/j.jad.2010.01.067
Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis
Abstract
Objective: To examine the validity of the Hospital Anxiety and Depression Scale (HADS) in the identification of psychiatric complications of cancer, as defined by a robust criterion standard.
Methods: 50 analyses tested the depression subscale (HADS-D), anxiety subscale (HADS-A) or combined scales (HADS-T) against syndromal (clinical) depression (n=22), syndromal anxiety (n=4) or any mental ill health/distress (n=24), all defined by semi-structured psychiatric interview.
Results: The HADS and its subscales had both strengths and limitations. Overall it appeared to perform marginally better in non-palliative cancer settings. Specific findings for each subscale were as follows. In the identification of depression the HADS-T, HADS-D and HADS-A had a pooled sensitivity and specificity of 82.0%, 77.0%; 71.6%, 82.6% and 80.5%, 77.8%, respectively. All versions performed poorly in case-finding but well in a screening capacity. For anxiety there were no HADS-D studies. The HADS-T and HADS-A had a pooled sensitivity and specificity of 83.9%, 69.9% and 48.7%, 78.7%. They were poor at case-finding but good as screening instruments. For distress (any mental ill health) the HADS-T, HADS-D and HADS-A had a pooled sensitivity and specificity of 72.8%, 80.6%; 75.7%, 66.3% and 65.7%, 71.3%, respectively. When screening for distress and anxiety the HADS-T was the optimal subscale.
Conclusion: For the identification of depression, anxiety or distress in cancer settings, the HADS (including subscales) is not recommended as a case-finding instrument but it may, subject to concerns about its length, be a suitable addition to screening programme.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
The HADS and the DT for screening psychosocial distress of cancer patients in Taiwan.Psychooncology. 2011 Jun;20(6):639-46. doi: 10.1002/pon.1952. Epub 2011 Mar 15. Psychooncology. 2011. PMID: 21626611
-
Screening for anxiety and depression after stroke: comparison of the hospital anxiety and depression scale and the Montgomery and Asberg depression rating scale.J Psychosom Res. 2009 Oct;67(4):325-32. doi: 10.1016/j.jpsychores.2009.03.007. Epub 2009 Apr 17. J Psychosom Res. 2009. PMID: 19773025
-
Psychiatric morbidity and its screening in Turkish women with breast cancer: a comparison between the HADS and SCID tests.Psychooncology. 2008 Jul;17(7):668-75. doi: 10.1002/pon.1286. Psychooncology. 2008. PMID: 17992701
-
[Anxiety, depression, cancer: clinical aspects].Encephale. 1998 Dec;24 Spec No 2:66-71. Encephale. 1998. PMID: 9949930 Review. French. No abstract available.
-
Mixed anxiety and depression: should it be included in DSM-IV?J Clin Psychiatry. 1993 May;54 Suppl:4-7; discussion 17-20. J Clin Psychiatry. 1993. PMID: 8509357 Review.
Cited by
-
Forming new habits in the face of chronic cancer-related fatigue: An interpretative phenomenological study.Support Care Cancer. 2021 Nov;29(11):6651-6659. doi: 10.1007/s00520-021-06252-3. Epub 2021 May 6. Support Care Cancer. 2021. PMID: 33954822 Free PMC article.
-
Video education about side effects of chemotherapy and immunotherapy and its impact on the anxiety, depression, and distress level of cancer patients.BMC Psychol. 2022 Nov 24;10(1):278. doi: 10.1186/s40359-022-00994-3. BMC Psychol. 2022. PMID: 36434673 Free PMC article.
-
Cancer-related search for meaning increases willingness to participate in mindfulness-based stress reduction.Integr Cancer Ther. 2015 May;14(3):231-9. doi: 10.1177/1534735415580682. Integr Cancer Ther. 2015. PMID: 25870034 Free PMC article.
-
Impact of the Cognitive-Behavioral Approach and Psychoeducational Intervention in Breast Cancer Management: A Prospective Randomized Clinical Trial.Healthcare (Basel). 2022 Mar 27;10(4):629. doi: 10.3390/healthcare10040629. Healthcare (Basel). 2022. PMID: 35455807 Free PMC article.
-
Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.Ther Adv Med Oncol. 2018 Nov 20;10:1758835918809610. doi: 10.1177/1758835918809610. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30479671 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical